Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2017
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CAPTIVATE
- Sponsors Pharmacyclics
- 14 Nov 2017 Planned number of patients changed from 150 to 289.
- 14 Nov 2017 Planned End Date changed from 1 Sep 2021 to 1 Dec 2020.
- 14 Nov 2017 Planned primary completion date changed from 1 Feb 2021 to 1 Dec 2020.